At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Oral Caffeine Decreases the Frequency of Opioid Demand in AIS Patients After Spinal Fusion
In Brief
A Phase 4 clinical trial evaluating Caffeine Tablet and Placebo for Adolescent Idiopathic Scoliosis. Completed, enrolled 61 participants across 1 site.
Detailed Summary
Prospective, randomized control trial To determine if oral caffeine decreases the frequency of opioid demand in children with adolescent idiopathic scoliosis after their spinal fusion surgery To compare pain scale ratings, number of requests for diazepam, average heart rate, average blood pressure, sex, age, ethnicity, post-op day of discharge, operative time, estimated intraoperative blood loss, remittance post-surgery, length of hospital stay, and segments fused during spinal fusion surgery.
Study Details
Timeline
Interventions
Caffeine is approved by the FDA as a stimulant. A stimulant approved by the United States Food and Drug Administration (FDA) for the treatment to increase mental alertness and in combination with painkiller to treat migraine headaches. It is approved in the form of pill or tablet.
Placebo, empty opaque dark blue blank capsule, taken twice daily. This will be an adjuvant to their standard pain control.